Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SelvitaFRA:787 75 EV-to-EBIT is 117.13 as of Aug. 09, 2026, which is 98% above its 10-year median of 59.23. GuruFocus rates FRA:787 with a GF Score™ of 75/100 and a GF Value™ of €13.38. The stock has 4 warning signs investors should review. Among 105 Medical Diagnostics & Research companies, Selvita ranks worse than 96.19% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Selvita's Enterprise Value is €151.80 Mil.
Selvita's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €1.30 Mil. Therefore, Selvita's EV-to-EBIT for today is 117.13.
The historical rank and industry rank for Selvita's EV-to-EBIT or its related term are showing as below:
FRA:787'
s EV-to-EBIT Range Over the Past 10 Years
Min: 14.79 Med: 59.23 Max: 409.52
Current: 118.6
During the past 11 years, the highest EV-to-EBIT of Selvita was 409.52. The lowest was 14.79. And the median was 59.23.
FRA:787's EV-to-EBIT is ranked worse than 96.19% of 105
companies
in the Medical Diagnostics & Research industry
Industry Median: 23.43
vs FRA:787: 118.60
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Selvita's Enterprise Value for the quarter that ended in Mar. 2026 was €179.07 Mil.
Selvita's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selvita EV-to-EBIT Related Terms
Selvita EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Selvita's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Selvita's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selvita EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Selvita's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Selvita's EV-to-EBIT falls into.
Selvita's current Enterprise Value is €151.80 Mil.
Selvita's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selvita (FRA:787) has a EV-to-EBIT of 117.13 as of Aug. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Selvita and its competitors. This is 98% above median its historical median of 59.23. Over the past decade, Selvita's EV-to-EBIT has ranged from 14.79 to 409.52. According to the industry distribution chart, Selvita ranks #101 out of 105 companies in the Medical Diagnostics & Research industry, placing it in the top 96.2%.
Is Selvita's EV-to-EBIT too high?
Selvita's current EV-to-EBIT of 117.13 is 98% above median its 10-year median of 59.23. Over the past 10 years, this metric has ranged from a low of 14.79 to a high of 409.52. The Medical Diagnostics & Research industry median EV-to-EBIT is 23.43. Selvita's value of 117.13 is 399.9% above this industry median. Based on the distribution chart, Selvita ranks #101 out of 105 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Selvita has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Selvita's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Selvita ranks #101 out of 105 companies for EV-to-EBIT. This places Selvita in the lower half of its industry. The industry median EV-to-EBIT is 23.43. Selvita's value of 117.13 is 399.9% above this benchmark. Historically, Selvita's own EV-to-EBIT has ranged from 14.79 to 409.52 over the past decade. While the company's 10-year median is 59.23 vs. the industry median of 23.43, Selvita has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.43, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Selvita's current EV-to-EBIT of 117.13 is 399.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Selvita and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Selvita's current EV-to-EBIT is 117.13, which is 98% above median its own 10-year median of 59.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selvita stock overvalued right now?
Selvita (FRA:787) has a current EV-to-EBIT of 117.13. The stock's GF Value™ is €13.38, compared to a current price of €6.29 — trading 53% below its estimated fair value. The current EV-to-EBIT is 117.13, which is 98% above median its 10-year median of 59.23 and 399.9% above the Medical Diagnostics & Research industry median of 23.43. Selvita's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Selvita (FRA:787), the current EV-to-EBIT is 117.13 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selvita (FRA:787) Overvalued in 2026?
Based on GuruFocus' analysis, Selvita stock appears to be undervalued.
The current stock price of €6.29 is trading 53% below its estimated GF Value™ of €13.38.
Key valuation signals for FRA:787:
EV-to-EBIT: 117.13 (98% above median its 10-year median of 59.23)
GF Value™: €13.38 vs. price of €6.29 (53% below fair value)
Industry Position: 399.9% above the Medical Diagnostics & Research median (#101 of 105)
No single metric tells the full story. See the FRA:787 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selvita SA is a Poland based parent company of Selvita Group is one of the largest preclinical contract research organizations in Europe. It also develops bioinformatics solutions supporting innovative projects at preclinical stages. It also provides services provided to external contractors are in the field of chemistry, analytics, regulatory, biochemistry and cell biology and also the integrated research and development projects.
75GF Score
Get the complete analysis for FRA:787
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:787 has been successfully added to your 
